American medical device maker Agilent Technologies has unveiled its Agilent SureSelect Cancer CGP Assay for somatic variant profiling for a broad range of solid tumour types.
Agilent SureSelect Cancer CGP Assay is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling (CGP) to advance precision oncology.
The company has developed the pan-cancer assay using an NGS panel that consists of 679 genes.
The genes have been globally curated from cancer databases and in partnership with clinical cancer researchers.
According to the medical device maker, the assay workflow is automatable, efficient, and flexible. It makes tumour molecular profiling more accessible to a wider clinical research community.
The biomarkers include important classes of somatic variants (SNVs, CNVs, indels, translocations, de novo gene fusions), as well as the immuno-oncology biomarkers TMB (tumour mutational burden), and MSI (microsatellite instability).
Agilent said that the biomarkers assist clinical and translational researchers in examining potential cancer therapeutics.
Agilent SureSelect Cancer CGP is based on the company’s library prep and target enrichment chemistry.
It supports as little as 10 ng of input and incorporates walkaway automation to increase lab efficiency and productivity, the medical device maker said.
The assay provides current, globally curated biomarker content for comprehensive molecular profiling of solid tumours.
The workflow features customisable data analysis choices, including customer bioinformatics pipelines, third-party software, and Alissa Interpret for tertiary analysis and reporting, Agilent said.
Agilent Genomics Division vice president and general manager Ronda Allen said: “We’re pleased to commercialise the SureSelect Cancer CGP assay, which leverages our SureSelect chemistry that can accommodate a low amount of starting material so that scientists can profile more quantity-limited samples.
“Library preparation and target enrichment can be automated either on the benchtop Magnis NGS prep system, which will markedly improve workflow efficiency, reducing the hands-on time from hours to only 15 minutes or on the Bravo NGS workstation, for scaling up to 96 samples per run.”
Recently, the company and PathAI collaborated to offer artificial intelligence (AI)-driven assay development solutions for biopharma research and clinical applications.
